Whole Genome Sequencing Reveals a RET Enhancer Risk Haplotype Associated with Hirschsprung Disease in Mowat Wilson Syndrome

This study demonstrates that whole-genome sequencing identified a high-risk *RET* enhancer haplotype as a key modifier of Hirschsprung disease penetrance in Mowat-Wilson syndrome, explaining the variable clinical expressivity observed in patients with *ZEB2* haploinsufficiency.

The Gist

The Big Picture: Why Do Twins (or Siblings) Look Different?

Imagine Mowat-Wilson Syndrome (MWS) as a house built with a specific, broken blueprint. The blueprint is a gene called ZEB2. When this blueprint has a major error (a "loss-of-function" mutation), the house is always built with certain problems: intellectual disability, distinctive facial features, and sometimes, a blocked plumbing system in the gut.

The plumbing problem is called Hirschsprung Disease (HSCR). It's like a section of the intestine that forgot to get its "wiring" (nerves), so it can't move poop along.

Here is the mystery the scientists were trying to solve:

• Patient A has the broken ZEB2 blueprint and also has the blocked plumbing (HSCR).
• Patient B has the exact same type of broken ZEB2 blueprint but has perfect plumbing.

If the main blueprint is broken in both, why does only one child have the plumbing issue? The scientists suspected there was a "hidden modifier" in the background—like a second, smaller glitch that only causes trouble when the main blueprint is already broken.

The Detective Work: Scanning the Whole Genome

The researchers acted like master detectives. Instead of just looking at the main broken blueprint (ZEB2), they used Whole Genome Sequencing (WGS). Think of this as reading the entire instruction manual of the human body, not just the one page with the error.

They looked at two families (a child and their parents) to see what else was different between the two patients.

1. The "Extra" Errors: They checked for other broken genes or missing chunks of DNA. They found a few tiny, random glitches in both kids, but none of them were in the right place to explain the plumbing problem.
2. The "Volume Knob" (The Real Culprit): They found the answer in a gene called RET.
   • RET is like the "volume knob" for the nerves in the gut. You need a loud enough signal for the nerves to grow and connect properly.
   • There is a specific set of 10 tiny switches (called a haplotype) near the RET gene.
   • Patient A (with HSCR): Inherited a "High-Risk" combination of switches from their dad. These switches act like a dimmer switch turned way down, making the RET signal very quiet.
   • Patient B (no HSCR): Inherited "Low-Risk" switches from both parents. Their RET signal is loud enough to work.

The "Double Whammy" Effect

Here is the magic of the discovery:

• Patient B had a broken ZEB2 blueprint, but their RET "volume knob" was loud enough to compensate. The gut nerves grew fine.
• Patient A had the broken ZEB2 blueprint AND a dimmed RET volume knob. The combination was too much. The gut nerves didn't get the signal they needed to finish their job, so the plumbing stayed blocked.

The Analogy:
Imagine trying to walk through a dark tunnel (the gut).

• ZEB2 is the person holding the flashlight. In MWS, the flashlight is broken and dim.
• RET is a second flashlight.
• Patient B has a broken main flashlight, but their second flashlight is brand new and bright. They can still see the path.
• Patient A has a broken main flashlight and their second flashlight is also dim (because of the high-risk genetic switches). Now, it's too dark to see, and they get stuck (Hirschsprung disease).

Why This Matters: The "Two-Strike" Rule

This paper changes how we think about genetic diseases.

1. It's not always just one gene: Even if a disease is called "monogenic" (caused by one gene), other common genetic variations can decide how bad the symptoms are.
2. The "Common" vs. "Rare" mix: The ZEB2 mutation is rare and severe. The RET switches are very common in the general population (many healthy people have them). But when a rare severe mutation meets a common "risk" combination, it creates a specific disease outcome.
3. Tissue Specificity: The researchers also looked at the brain and the gut. They found that ZEB2 and RET work together in the gut (where the nerves are), but they don't really talk to each other in the brain. This explains why the plumbing issue is specific to the gut and not the brain, even though both organs are affected by the ZEB2 mutation.

The Takeaway

This study is like finding the missing piece of a puzzle. It shows that to understand why some people with Mowat-Wilson Syndrome get Hirschsprung disease and others don't, we have to look at the entire genetic landscape, not just the main broken gene.

By finding these "hidden modifiers," doctors might one day be able to predict which children with MWS are at risk for gut problems before they are even born, allowing for earlier monitoring and better care. It turns a "one-size-fits-all" diagnosis into a personalized roadmap for each patient.

Technical Summary

1. Problem Statement

Mowat-Wilson Syndrome (MWS) is a rare neurodevelopmental disorder caused by heterozygous loss-of-function (LoF) variants in the ZEB2 gene. While all confirmed MWS cases share this primary genetic lesion, there is significant variable expressivity in clinical presentation. Specifically, Hirschsprung disease (HSCR)—a congenital defect of the enteric nervous system (ENS)—occurs in only ~40% of MWS patients.

The central question addressed by this study is: What genetic factors determine why some MWS patients develop HSCR while others do not, despite sharing the same primary ZEB2 diagnosis? The authors hypothesize that beyond the primary ZEB2 mutation, additional genetic modifiers (either rare coding variants or common regulatory variants) influence the penetrance of HSCR.

2. Methodology

The study employed a multi-omics approach combining Whole-Genome Sequencing (WGS), haplotype phasing, and single-cell transcriptomics.

• Cohort Selection: Two parent-child trios were analyzed:
  • Proband 1 (MWS1.1): Diagnosed with MWS and long-segment HSCR.
  • Proband 2 (MWS2.1): Diagnosed with MWS but without HSCR.
  • Both probands carry pathogenic de novo ZEB2 variants.
• Genomic Analysis:
  • WGS: Performed at 30x coverage on Illumina platforms.
  • Variant Calling: Used DeepVariant for SNVs/indels, Manta/Delly for structural variants, and Exomiser for prioritization.
  • Copy Number Variation (CNV): Assessed using CNPI (Copy Number Polygenic Index) to calculate an Individual-Level Copy Number Score (ICNS) to detect excess genomic burden.
  • Haplotype Phasing: Specifically analyzed a previously defined 10-SNP enhancer haplotype at the RET locus (a key gene for ENS development). The authors reconstructed parental transmission to determine if the probands inherited high-risk or low-risk haplotypes.
• Functional Validation (In Silico):
  • Single-Cell RNA Sequencing (scRNA-seq): Re-analyzed data from the Human Gut Cell Atlas (fetal gut, 6–11 weeks post-conception) and a cortical development atlas to assess the co-expression of ZEB2 and RET in specific cell lineages (neural crest, neuroblasts, glia).

3. Key Results

A. Primary Genetic Diagnosis

• Both probands harbored pathogenic de novo LoF variants in ZEB2:
  • MWS1.1: Frameshift variant p.(Lys284Asnfs*30) (affecting the N-terminal zinc-finger cluster).
  • MWS2.1: Stop-gained variant p.(Arg671*) (disrupting the homeodomain).
• Both variants fall within regions of the protein known to be enriched for pathogenic variants in neurodevelopmental disorders.

B. Exclusion of Other Modifiers

• Rare Coding Variants: Aside from ZEB2, only two additional missense variants were found (in RNASEH2C and TULP4). Expression analysis showed these genes are not expressed in enteric neural crest progenitors, making them unlikely drivers of HSCR.
• Copy Number Burden: ICNS analysis revealed no significant excess of pathogenic CNVs in either proband compared to the general population, ruling out large-scale genomic instability as the cause of phenotypic divergence.

C. The RET Enhancer Haplotype (The Critical Finding)

• MWS1.1 (HSCR+): Inherited a high-risk paternal RET enhancer haplotype (sequence: GCAGGTTGGT) with an Odds Ratio (OR) of 11.01. The maternal haplotype was low-risk (OR 2.01).
• MWS2.1 (HSCR-): Inherited low-risk haplotypes from both parents (OR 1.33).
• Mechanism: Previous functional studies cited by the authors indicate this high-risk haplotype reduces RET regulatory output by >50%. In the context of ZEB2 haploinsufficiency, this further reduction in RET signaling pushes the system below the critical threshold required for ENS development, triggering HSCR.

D. Tissue-Specific Expression Context

• Enteric Nervous System (ENS): scRNA-seq data confirmed that ZEB2 and RET are co-expressed in enteric neural crest cells (ENCCs), neuroblasts, and early neuronal lineages during fetal development. This provides the biological substrate for their interaction.
• Neocortex: In contrast, while ZEB2 is broadly expressed in the developing neocortex, RET expression is largely absent. This explains why RET regulatory variation specifically modifies the gastrointestinal phenotype (HSCR) rather than the neurodevelopmental phenotype (intellectual disability) in MWS.

4. Key Contributions

1. Identification of a Modifier: Demonstrated that a common, non-coding RET enhancer haplotype acts as a genetic modifier for HSCR penetrance in MWS.
2. Resolution of Variable Expressivity: Provided a mechanistic model where a primary Mendelian lesion (ZEB2 LoF) creates a sensitized background, and a secondary common variant (RET enhancer) determines whether a specific organ system (ENS) fails.
3. Methodological Demonstration: Showed that Whole-Genome Sequencing is essential even in "monogenic" disorders to uncover regulatory modifiers that standard exome sequencing or single-gene testing would miss.
4. Tissue-Specificity: Validated through scRNA-seq that the interaction between ZEB2 and RET is specific to the ENS lineage, explaining the tissue-specific nature of the phenotypic variability.

5. Significance and Implications

• Clinical Diagnostics: This study argues that for syndromes with variable expressivity (like MWS), genetic counseling and prognosis should not rely solely on the primary gene diagnosis. Assessing common regulatory haplotypes in modifier genes (like RET) could improve risk stratification for HSCR.
• Genomic Architecture: It supports a "layered" model of genetic risk where high-impact coding variants and common regulatory variants interact to determine phenotypic outcomes.
• Future Research: Highlights the need to prioritize modifier gene discovery within specific cellular contexts (e.g., ENS progenitors) rather than looking at the whole genome in isolation.
• Broader Impact: The findings suggest that many "monogenic" disorders may actually be oligogenic or influenced by complex regulatory backgrounds, necessitating a shift toward integrative genomic approaches in neurocristopathies and developmental disorders.

Conclusion: The paper successfully identifies a specific RET enhancer risk haplotype as the missing link explaining why one MWS patient developed Hirschsprung disease while another with a similar primary mutation did not, illustrating the critical role of common regulatory variation in modifying Mendelian disease penetrance.